Cell Reports (Jan 2018)
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- Xiangyi Li,
- GuemHee Baek,
- Susmita G. Ramanand,
- Adam Sharp,
- Yunpeng Gao,
- Wei Yuan,
- Jon Welti,
- Daniel N. Rodrigues,
- David Dolling,
- Ines Figueiredo,
- Semini Sumanasuriya,
- Mateus Crespo,
- Adam Aslam,
- Rui Li,
- Yi Yin,
- Bipasha Mukherjee,
- Mohammed Kanchwala,
- Ashley M. Hughes,
- Wendy S. Halsey,
- Cheng-Ming Chiang,
- Chao Xing,
- Ganesh V. Raj,
- Sandeep Burma,
- Johann de Bono,
- Ram S. Mani
Affiliations
- Xiangyi Li
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- GuemHee Baek
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Susmita G. Ramanand
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Adam Sharp
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Yunpeng Gao
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Wei Yuan
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Jon Welti
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Daniel N. Rodrigues
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- David Dolling
- Clinical Trials and Statistics Unit, Institute of Cancer Research, London SM2 5NG, UK
- Ines Figueiredo
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Semini Sumanasuriya
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Mateus Crespo
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Adam Aslam
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Rui Li
- Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Yi Yin
- Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Bipasha Mukherjee
- Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Mohammed Kanchwala
- Eugene McDermott Center for Human Growth & Development, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Ashley M. Hughes
- Target Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA
- Wendy S. Halsey
- Target Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA
- Cheng-Ming Chiang
- Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Chao Xing
- Eugene McDermott Center for Human Growth & Development, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Ganesh V. Raj
- Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Sandeep Burma
- Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- Johann de Bono
- Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
- Ram S. Mani
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
- DOI
- https://doi.org/10.1016/j.celrep.2017.12.078
- Journal volume & issue
-
Vol. 22,
no. 3
pp. 796 – 808
Abstract
BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated antitumor activity against multiple cancer types. We show that BRD4 is essential for the repair of DNA double-strand breaks (DSBs) and mediates the formation of oncogenic gene rearrangements by engaging the non-homologous end joining (NHEJ) pathway. Mechanistically, genome-wide DNA breaks are associated with enhanced acetylation of histone H4, leading to BRD4 recruitment, and stable establishment of the DNA repair complex. In support of this, we also show that, in clinical tumor samples, BRD4 protein levels are negatively associated with outcome after prostate cancer (PCa) radiation therapy. Thus, in addition to regulating gene expression, BRD4 is also a central player in the repair of DNA DSBs, with significant implications for cancer therapy.
Keywords
- BRD4
- BRD2
- DNA repair
- non-homologous end joining
- NHEJ
- gene fusion
- genomic rearrangements
- TMPRSS2-ERG
- prostate cancer
- CRPC